Lipicure CV 20mg/75mg Capsule

Clopidogrel, an antiplatelet agent, inhibits adenosine diphosphate (ADP)-induced platelet aggregation by irreversibly binding to the P2Y12 receptor on platelets, preventing thrombus formation. This combination is particularly beneficial in patients with a history of acute coronary syndrome, recent myocardial infarction, stroke, or peripheral arterial disease, where both lipid control and platelet inhibition are critical to prevent recurrent ischemic events.

Lipicure CV should be administered under medical supervision, considering potential drug interactions and contraindications such as active bleeding or hypersensitivity to components. Regular monitoring of lipid profiles, liver function tests, and hematological parameters is recommended during therapy. Adverse effects may include gastrointestinal disturbances, myalgia, bleeding tendencies, and rare but serious events like hepatotoxicity or thrombotic thrombocytopenic purpura.

Patient adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes.